In addition to EGFR-expressing cancer cells being targeted, bystander killing effects may contribute to ADC efficacy through the release of the membrane-permeable payloads from the internalizing cell following linker cleavage or by payload release following cancer cell death. The gene discussed is EGFR; the disease is cancer.